A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma

Annals of Surgery

Volumn 260, Issue 1, 2014, Pages 142-148

  O'Reilly, Eileen M ^a   Perelshteyn, Anna ^a   Jarnagin, William R ^a   Schattner, Mark ^a   Gerdes, Hans ^a   Capanu, Marinela ^a   Tang, Laura H ^a   Lavalle, Joseph ^a   Winston, Corinne ^a   Dematteo, Ronald P ^a   D'Angelica, Michael ^a   Kurtz, Robert C ^a   Abou Alfa, Ghassan K ^a   Klimstra, David S ^a   Lowery, Maeve A ^a   Brennan, Murray F ^a   Coit, Daniel G ^a   Reidy, Diane L ^a   Kingham, T Peter ^a   Allen, Peter J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

gemcitabine; neoadjuvant; oxaliplatin; pancreas adenocarcinoma; resectable

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; OXALIPLATIN; TRIACYLGLYCEROL LIPASE; TUMOR MARKER;

ABDOMINAL PAIN; ABSCESS; ADULT; ALLERGIC REACTION; ANEMIA; ANXIETY DISORDER; ARTICLE; ASCITES; ASPIRATION CYTOLOGY; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHOLANGITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; ENDOSCOPIC ECHOGRAPHY; ERYTHEMA MULTIFORME; EXTRAVASATION; FATIGUE; FEMALE; FEVER; FINE NEEDLE ASPIRATION CYTOLOGY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMORRHOID; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOGLYCEMIA; INFECTION; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LAPAROSCOPY; LETHARGY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ANGIOGRAPHY; PANCREAS RESECTION; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RASH; RESECTABLE PANCREAS ADENOCARCINOMA; SPLENECTOMY; SUDDEN CARDIAC DEATH; THROMBOCYTE; THROMBOCYTE ANOMALY; TUMOR BIOPSY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84902174669     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000251     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169-175.
3. O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol. 2013;107:78-85.
4. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
6. Chandler NM, Canete JJ, Stuart KE, et al. Preoperative chemoradiation in resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2003;10:61-66.
7. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
8. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5- fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782; discussion 782-784.
9. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-1234.
10. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057.
11. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg. 2008;12:1600-1608.
12. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89:314-327.
13. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8:758-765.
14. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158.
15. Pipas JM, Barth RJ Jr, Zaki B, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2005;12:995-1004.
16. Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23:4538-4544.
17. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16:317-323.
18. Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 2000;135:81-87; discussion 88.
19. Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:2526-2531.
20. Heinrich S, Schafer M,Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014-1022.
21. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
22. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004;28:215-223.
23. Belli C, Cereda S, Anand S, et al. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev. 2013;39:518-524.
24. Hoffman JP. Status of neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am. 2010;19:411-418.
25. Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117:2044-2049.
26. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/ neoadjuvant therapy in pancreatic cancer: a systematic review and metaanalysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
27. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473.
28. Chua TC, Saxena A. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results. Surg Oncol. 2011;20:e161-e168.
29. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495.
30. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
31. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol. 2012;30(suppl 34):LBA148.
32. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-5756.
33. Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100:246-250.
34. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319-1326.
35. Ueseka K, Fukitami A, Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patientswith resected pancreatic cancer (JASPAC-01 study). J Clin Oncol. 2012;30(suppl 34):145.